3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
8
Recruiting
5
Withdrawn
2
Terminated
2
Unknown
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
2
Neoplasm, Residual
1
Interventions
Cyclophosphamide
128
Cisplatin
119
Radiotherapy
111
pembrolizumab
110
Paclitaxel
96
Gemcitabine
96
Carboplatin
96
Nivolumab
76
Magnetic Resonance Spectroscopy
76
Bevacizumab
76
Fluorouracil
74
Dexamethasone
73
Radiosurgery
66
Docetaxel
59
Rituximab
58
Leucovorin
57
Oxaliplatin
55
Capecitabine
55
Doxorubicin
52
fludarabine
51
Biopsy
48
durvalumab
44
Cytarabine
44
Drug Therapy
43
Etoposide
42
fludarabine phosphate
40
Pemetrexed
40
Radiation
39
atezolizumab
36
Lenalidomide
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
Interventional
×
posaconazole
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn
NCT03036046
2018-02-15
SAFEGUARDFP
F2G Biotech GmbH
Phase 1/2
Withdrawn